Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects

Trial Profile

A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects

Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Sep 2018

At a glance

  • Drugs Maraviroc (Primary) ; Efavirenz; Lamivudine/zidovudine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms MERIT; MERIT-ES
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 07 Sep 2018 Results published in the Journal of Clinical Pharmacology
    • 31 Aug 2018 Biomarkers information updated
    • 27 Oct 2017 Results of post-hoc analysis (n=895) assessing the effect of maraviroc versus efavirenz on the CD4/CD8 ratio dynamics, presented at the 16th European AIDS Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top